The hydrogel spacer minimizes radiation exposure to the rectum, decreasing bowel, urinary, and sexual complications. Recent analysis reveals that rectal spacers significantly lower recurrence rates in ...

Dr. Colette Shen discusses unmet needs in recurrent head and neck cancer, highlighting a novel treatment study aimed at ...

Results from a phase 1-2 clinical study (NCT05296122) 1 showed that safety and feasibility measures among patients with primary and recurrent glioblastoma and grade 4 astrocytoma could be met using ...

The Paloma-3 study provided important insights into patient-reported outcomes with the subcutaneous formulation of amivantamab. Historically, cancer treatment focused primarily on ...

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation ...

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent ...

Discover how NBTXR3 enhances radiation therapy for head and neck cancer, boosting treatment efficacy while protecting healthy ...

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, ...

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...

The US FDA has accepted the supplemental biologics license application (sBLA) for trastuzumab deruxtecan (T-DXd; Enhertu) ...